Depression, a significant cause of disability in the United States, is largely managed by primary care providers; therefore, understanding how these clinicians manage depression is an important step toward identifying opportunities for improvement.
Recommendations for pharmacotherapy with antipsychotics as both acute and maintenance treatment of schizophrenia were made following a systematic literature review of current clinical practice guidelines.
Post-hoc analyses of pooled data from the randomized, double-blind ASPIRE 1 and ASPIRE II studies were conducted to assess the effect of esketamine in adult patients with major depressive disorder and active suicidal ideation.
Researchers report on the 52-week extension of the ENLIGHTEN-2 study that assessed the long-term safety and efficacy of treatment schizophrenia with olanzapine and samidorphan.
A pooled analysis evaluated reductions in migraine and headache days among patients with chronic migraine and comorbid depression in 2 placebo-controlled, phase 3 trials of fremanezumab.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.
In order to assess the efficacy and safety of JZP-258, a lower sodium alternative product to sodium oxybate, study authors designed a double-blind, placebo-controlled, randomized withdrawal, multicenter study with an open-label safety extension.
Researchers used data from the National Health and Nutrition Examination Survey 2009-2018 to assess the impact of drug and alcohol use on cardiometabolic disease risk factors.
